Wikipedia

Ottawa Hospital Research Institute

The Ottawa Hospital Research Institute (OHRI), formerly Ottawa Health Research Institute,[1] is a non-profit academic health research institute located in the city of Ottawa. It was formed in 2001 following the merger of three Ottawa hospitals. The Ottawa Hospital Research Institute is the research arm of The Ottawa Hospital and affiliated with the University of Ottawa.

As of 2022, the Ottawa Hospital Research Institute houses approximately 2,200 scientists, clinician investigators, students, research fellows, and support staff.[2][3] It has five research programs: Cancer Therapeutics; Chronic Disease; Clinical Epidemiology; Regenerative Medicine; and Neurosciences.[4] Its researchers are studying more than a hundred different diseases, conditions and specialties with an overall focus on translating discoveries and knowledge into better health.[2]

Ronald G. Worton was the research institute's founding CEO and Scientific Director in 2001.[5] In 2007, Duncan Stewart, formerly Chief Cardiologist of St. Michael's Hospital in Toronto and Director of Cardiology of University of Toronto, took over as CEO and Scientific Director.[6][7]

History

edit

COVID-19

edit

During the COVID-19 pandemic, scientists at the OHRI developed an early-stage COVID-19 vaccine candidate called TOH-Vac1.[8] The candidate is a live replicating virus vaccine using a vaccinia virus vector.[9] Results from pre-clinical studies were published in Molecular Therapy in October 2021.[10] The research team was led by John Bell and was funded by the Thistledown Foundation, Ottawa Hospital Foundation and the Canadian Institutes of Health Research.[11]

Notable discoveries and accomplishments

edit
  • Harold Atkins and Mark Freedman pioneered the use of autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis.[12]
  • Michael Rudnicki was the first to characterize adult skeletal muscle stem cells.[13]
  • Ian Stiell developed the Ottawa ankle rules.
  • David Moher led the development of the CONSORT reporting guidelines for clinical trials and the PRISMA reporting guidelines for systematic reviews and meta-analyses.
  • Doug Manuel developed ProjectBigLife,[14] a life expectancy calculator that helps educate people about healthy lifestyle choices.
  • John Bell and his colleagues demonstrated for the first time that an intravenously-delivered viral therapy can selectively infect and spread within tumours in humans.[15]
  • Dean Fergusson and Paul Hebert discovered that aprotinin is associated with an increased risk of death compared to other drugs routinely used to prevent blood loss during heart surgery.[16]
  • Annette O'Connor pioneered the use of Patient Decision Aids.[17]
  • Natasha Kekre is leading the first clinical trial of made-in-Canada CAR-T cells for the treatment of cancer.[18]

Notable faculty and alumni

edit

References

edit
  1. ^ Ottawa Hospital Research Institute (April 22, 2009). "Ottawa Health Research Institute changes name to Ottawa Hospital Research Institute". Retrieved June 5, 2014.
  2. ^ a b "Ottawa Hospital Research Institute". www.ohri.ca. Retrieved 2022-11-02.
  3. ^ "Our People". Ottawa Hospital Research Institute. Archived from the original on 2013-07-02.
  4. ^ "Research Programs". Ottawa Hospital Research Institute.
  5. ^ "Dr. Ronald Worton, Founding CEO of the Ottawa Hospital Research Institute, to be inducted into the Canadian Medical Hall of Fame". Ottawa Hospital Research Institute. September 24, 2013.
  6. ^ "Dr. Duncan Stewart, science director at the Ottawa Hospital Research Institute, has been named to head up the Canadian Vascular Network". Ottawa Citizen. February 23, 2014. Archived from the original on June 9, 2014.
  7. ^ "Ottawa Health Research Institute holds Annual General Meeting and welcomes new CEO". Ottawa Hospital Research Institute. September 24, 2007.
  8. ^ Department of Biochemistry, Microbiology and Immunology (2021-12-13). "Made-in-Ottawa vaccine could help in global fight against COVID-19, including new variants". University of Ottawa. Archived from the original on 2023-03-19. Retrieved 2023-03-19.
  9. ^ Rudnicki, Jonathan (2021-12-30). "Scientific team behind Ottawa-made COVID-19 vaccine aims to support long-term global response to pandemic". Capital Current. Archived from the original on 2023-03-19. Retrieved 2023-03-19.
  10. ^ Boulton, Stephen; Poutou, Joanna; Martin, Nikolas T.; Azad, Taha; Singaravelu, Ragunath; Crupi, Mathieu J. F.; Jamieson, Taylor; He, Xiaohong; Marius, Ricardo; Petryk, Julia; Souza, Christiano Tanese de; Austin, Bradley; Taha, Zaid; Whelan, Jack; Khan, Sarwat T. (2022-05-04). "Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection". Molecular Therapy. 30 (5): 1885–1896. doi:10.1016/j.ymthe.2021.10.008. ISSN 1525-0016. PMC 8527104. PMID 34687845.
  11. ^ Duffy, Andrew (2021-12-16). ""Versatile" made-in-Ottawa COVID-19 vaccine ready for human trials". Ottawa Citizen. Archived from the original on 2021-12-18. Retrieved 2023-03-19.
  12. ^ Atkins, Harold L.; Bowman, Marjorie; Allan, David; Anstee, Grizel; Arnold, Douglas L.; Bar-Or, Amit; Bence-Bruckler, Isabelle; Birch, Paul; Bredeson, Christopher; Chen, Jacqueline; Fergusson, Dean; Halpenny, Mike; Hamelin, Linda; Huebsch, Lothar; Hutton, Brian (2016-08-06). "Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial". The Lancet. 388 (10044): 576–585. doi:10.1016/S0140-6736(16)30169-6. ISSN 0140-6736. PMID 27291994. S2CID 4530484.
  13. ^ Kuang, Shihuan; Kuroda, Kazuki; Le Grand, Fabien; Rudnicki, Michael A. (2007-06-01). "Asymmetric self-renewal and commitment of satellite stem cells in muscle". Cell. 129 (5): 999–1010. doi:10.1016/j.cell.2007.03.044. ISSN 0092-8674. PMC 2718740. PMID 17540178.
  14. ^ "Project Big Life". www.projectbiglife.ca.
  15. ^ Breitbach, Caroline J.; Burke, James; Jonker, Derek; Stephenson, Joe; Haas, Andrew R.; Chow, Laura Q. M.; Nieva, Jorge; Hwang, Tae-Ho; Moon, Anne; Patt, Richard; Pelusio, Adina; Le Boeuf, Fabrice; Burns, Joe; Evgin, Laura; De Silva, Naomi (2011-08-31). "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans". Nature. 477 (7362): 99–102. doi:10.1038/nature10358. ISSN 1476-4687. PMID 21886163. S2CID 4365604.
  16. ^ Fergusson, Dean A.; Hébert, Paul C.; Mazer, C. David; Fremes, Stephen; MacAdams, Charles; Murkin, John M.; Teoh, Kevin; Duke, Peter C.; Arellano, Ramiro; Blajchman, Morris A.; Bussières, Jean S.; Côté, Dany; Karski, Jacek; Martineau, Raymond; Robblee, James A. (2008-05-29). "A comparison of aprotinin and lysine analogues in high-risk cardiac surgery". The New England Journal of Medicine. 358 (22): 2319–2331. doi:10.1056/NEJMoa0802395. ISSN 1533-4406. PMID 18480196.
  17. ^ "About Us - Patient Decision Aids - Ottawa Hospital Research Institute". decisionaid.ohri.ca.
  18. ^ Duffy, Andrew (April 8, 2021). "Treating the untreatable: How and why Canada's CAR-T network was built". Ottawa Citizen.
  19. ^ "Ottawa Hospital Research Institute". www.ohri.ca.
  20. ^ "Ottawa Hospital Research Institute". www.ohri.ca.
  21. ^ "Ottawa Hospital Research Institute". www.ohri.ca.
  22. ^ "Ottawa Hospital Research Institute". www.ohri.ca.
edit

45°23′35″N 75°43′26″W / 45.39307°N 75.72391°W / 45.39307; -75.72391

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ottawa_Hospital_Research_Institute&oldid=1208967420"